N. Hosea

发表

Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling

Hannah M Jones, Maurice Dickins, Barry C Jones, 2011, Clinical pharmacokinetics.

Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

P. Wei, T. Smeal, N. Hosea, 2010, Molecular Cancer Therapeutics.

Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4′-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys

A. Fanjul, P. Rejto, P. Stewart, 2008, Journal of Pharmacology and Experimental Therapeutics.

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding

Zhou Zhu, A. Fanjul, P. Rejto, 2012, BMC Genomics.

Purification of Cytochrome P‐450 Enzymes

F. Guengerich, M. Martín, N. Hosea, 1999, Current protocols in toxicology.

Aspartate 74 as a primary determinant in acetylcholinesterase governing specificity to cationic organophosphonates.

I. Tsigelny, P. Taylor, Z. Radić, 1996, Biochemistry.

The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.

A. Fanjul, P. Rejto, G. Paderes, 2010, Bioorganic & medicinal chemistry letters.

Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b5.

F. Guengerich, D. V. Thompson, N. Hosea, 1997, Archives of biochemistry and biophysics.

Phase I study of PF-04554878, a second-generation focal adhesion kinase (FAK) inhibitor, in patients with advanced solid tumors.

G. Shapiro, S. Shreeve, Philippe Bédard, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Structural bases for the specificity of cholinesterase catalysis and inhibition.

P. Taylor, Z. Radić, P. Marchot, 1995, Toxicology letters.

Mechanism of oxime reactivation of acetylcholinesterase analyzed by chirality and mutagenesis.

P. Taylor, L. Wong, Z. Radić, 2000, Biochemistry.

Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration

J. Cianfrogna, F. Nelson, Xingrong Liu, 2006, Drug Metabolism and Disposition.

Inactivation studies of acetylcholinesterase with phenylmethylsulfonyl fluoride.

J. Sussman, P. Taylor, I. Silman, 2000, Molecular pharmacology.

THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL

Xi Chen, Karthik Venkatakrishnan, Matthew Troutman, 2005, Drug Metabolism and Disposition.

Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches

Bill J Smith, T. Maurer, K. Beaumont, 2009, Journal of clinical pharmacology.

Factors Affecting the Clinical Development of Cytochrome P450 3A Substrates

M. Gibbs, N. Hosea, 2003, Clinical pharmacokinetics.

Specificity and orientation of trigonal carboxyl esters and tetrahedral alkylphosphonyl esters in cholinesterases.

P Taylor, P. Taylor, N. Hosea, 1995, Biochemistry.

Analysis of cholinesterase inactivation and reactivation by systematic structural modification and enantiomeric selectivity.

I. Tsigelny, P. Taylor, L. Wong, 1999, Chemico-biological interactions.

Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs.

T. Shimada, F. Guengerich, E. Gillam, 1998, Drug metabolism and disposition: the biological fate of chemicals.

Determining ligand orientation and transphosphonylation mechanisms on acetylcholinesterase by Rp, Sp enantiomer selectivity and site-specific mutagenesis.

I. Tsigelny, P. Taylor, Z. Radić, 1997, Enantiomer.

Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.

A. Fanjul, M. Pairish, S. Greasley, 2012, Bioorganic & medicinal chemistry letters.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

M. Gleave, A. Zoubeidi, A. Fanjul, 2011, Journal of medicinal chemistry.

Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

Ernesto Callegari, Bill J Smith, J. Cianfrogna, 2005, Journal of Pharmacology and Experimental Therapeutics.

Oxidation of nonionic detergents by cytochrome P450 enzymes.

F. Guengerich, N. Hosea, 1998, Archives of biochemistry and biophysics.

Elucidation of distinct ligand binding sites for cytochrome P450 3A4.

G. Miller, F. Guengerich, F P Guengerich, 2000, Biochemistry.

Drug design tools--in silico, in vitro and in vivo ADME/PK prediction and interpretation: is PK in monkey an essential part of a good human PK prediction?

N. Hosea, 2011, Current topics in medicinal chemistry.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11β-hydroxysteroid dehydrogenase type 1: strategies to eliminate reactive metabolites.

A. Fanjul, P. Rejto, M. Edwards, 2013, Bioorganic & medicinal chemistry letters.

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275.

A. Fanjul, M. Edwards, J. Ermolieff, 2009, Bioorganic & medicinal chemistry letters.

Intermittent Oral Coadministration of a Gamma Secretase Inhibitor with Dexamethasone Mitigates Intestinal Goblet Cell Hyperplasia in Rats

N. Hosea, L. A. Burns-Naas, S. Randolph, 2014, Toxicologic pathology.

Intermittent Oral Coadministration of a Gamma Secretase Inhibitor with Dexamethasone Mitigates Intestinal Goblet Cell Hyperplasia in Rats

N. Hosea, L. A. Burns-Naas, S. Randolph, 2014, Toxicologic pathology.